...
首页> 外文期刊>Interventional neuroradiology: journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences >Treatment of vertebral artery origin stenosis with a Pharos stent device: a single center experience.
【24h】

Treatment of vertebral artery origin stenosis with a Pharos stent device: a single center experience.

机译:用Pharos支架装置治疗椎动脉源性狭窄:单中心经验。

获取原文
获取原文并翻译 | 示例

摘要

Atherosclerotic stenosis of vertebral artery (VA) origin exceeding 70% severity accounts for one third of all vertebrobasilar strokes. For a period of one year the results of endovascular treatment of VA stenosis with the new Pharos stent device were assessed.Twenty-two patients with symptomatic VA stenosis were treated with the Pharos stent. Clinical status and stenosis grade were documented before treatment and 24 hours, one, three and twelve months after treatment via ultrasound and magnetic resonance tomography.All procedures proved to be technically successful without the occurrence of intra-procedural complications. During the observation period of more than one year, 55% of patients were documented with a mean stenosis degree of 60%: two (10%) of these patients showed a residual stenosis after angioplasty and nine patients (45%) an in-stent restenosis, whereas only two patients were documented with a hemodynamically relevant in-stent restenosis of 80%. These two patients were retreated with balloon dilatation. None of the patients showed neurological deterioration or new abnormalities at magnetic resonance tomography examination. Neither VA occlusion nor restenosis of the contralateral VA negatively affected the clinical outcome. An in-stent restenosis was developed by more female than male patients.VA origin stenting with the Pharos stent device is an effective treatment of stenosis. The good clinical results compared to the high restenosis rates have to be examined in further studies. Pin particular, it has to be determined whether the Pharos stent allows the vessel time for collateralization, whether double antiplatelet treatment prevents recurrent cerebrovascular events or whether merely the low restenosis degree is causative for the clinical outcome.
机译:椎动脉狭窄程度超过70%的椎动脉粥样硬化狭窄占所有椎基底动脉卒中的三分之一。在为期一年的评估中,评估了使用新型Pharos支架装置进行血管狭窄的血管内治疗的结果。对22例有症状VA狭窄的患者进行了Pharos支架的治疗。通过超声和​​磁共振断层扫描记录治疗前和治疗后24小时,1、3、12个月的临床状况和狭窄程度,所有方法均在技术上被证明是成功的,没有发生过程内并发症。在超过一年的观察期内,有55%的患者被记录为平均狭窄度为60%:其中有2(10%)的患者在血管成形术后显示残余狭​​窄,而9例(45%)的患者在支架内再狭窄,而只有2例患者的血流动力学相关支架内再狭窄记录为80%。这两名患者接受了球囊扩张治疗。磁共振断层扫描检查均未显示神经系统恶化或新异常。对侧VA的VA闭塞或再狭窄均不会对临床结果产生负面影响。女性多于男性患者发展为支架内再狭窄。采用Pharos支架装置的VA支架置入术是治疗狭窄的有效方法。与再狭窄率高相比,良好的临床结果必须在进一步研究中进行检查。特别是,必须确定Pharos支架是否允许血管时间进行抵押,双重抗血小板治疗是否可以防止复发性脑血管事件或仅低的再狭窄程度是否会导致临床结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号